Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

NCT07035561 is registered in ClinicalTrials.gov with Shereen Medhat Mohammed Elsayed Nassar as lead sponsor.

NCT NCT07035561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07035561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis
Lead sponsor
Shereen Medhat Mohammed Elsayed Nassar
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2023
Completion date
January 31, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypersenstivity pneumonitis, ild